King warned on Embeda VNRs

Share this article:
Video news releases (VNRs) for King's abuse-resistant pain drug Embeda drew a warning letter from FDA's Division of Drug Marketing, Advertising and Communications.

The agency said two VNRs omitted or minimized risks, including those featured in the drug's “extensive” Boxed Warning, and failed to present limitations to the approved indication. Moreover, the warning letter said King presented misleading claims – among them, those about the drug's alleged abuse-resistant properties, which have not been substantiated clinically.  

DDMAC said King agreed to pull the VNRs in August following a teleconference with regulators.

The analgesic, approved in August for the management of moderate to severe pain, contains morphine sulfate and carries a long boxed warning against potentially fatal consequences of abuse, use with alcohol and improper administration.

The agency demanded that the company furnish a list of promotional materials it has pulled, and that it disseminate corrective messaging to counteract the violative releases.

Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.